Biotech and Life Science Investors
A verified directory of 231 biotech investors — sorted by platform versus asset thesis, where the first cheque lands, and what kind of capital it is.
Last verified
- 231
- Biotech investors
- 128
- Firms
- 33%
- Write the first cheque
- 13%
- Non-dilutive capital
Verified in the last 30 days
With a live life science mandate
Company creation or seed
Foundation or disease-focused money
Free preview
6 of 231 profiles
Names, roles, companies and live signals are public. Verified emails and LinkedIn URLs stay masked until you sign in.
- 01
Evanthia Karlsson-Obiora
General Partner · Thistledown Life Sciences
Kendall Square, Cambridge
Closed a $310M fourth fund in March; five platform cheques written since.
- Platform-first
- Dedicated fund
- Fresh vehicle
- Deploying
- e•••••@thistledownls.com Locked
- 02
Reuben Achterberg-Sowande
Managing Director · Coldharbour Venture Creation
Mission Bay, San Francisco
Founds two companies a year in-house; currently recruiting a CEO for an oncology asset.
- Venture creation
- Company creation
- Board control
- Recruiting CEO
- r•••••@coldharbourvc.com Locked
- linkedin.com/in/•••••• Locked
- 03
Marguerite Dlamini-Hollenbach
Partner · Stonecroft Asset Partners
Midtown, New York
Asset-only mandate; passed on every platform pitch in the last twelve months.
- Asset-first
- Series A
- Narrow mandate
- Fast no
- m•••••@stonecroftap.com Locked
- linkedin.com/in/•••••• Locked
- 04
Hiroyuki Bellingham-Osagie
Investment Director · Vantbrooke Pharma Ventures
Basking Ridge, NJ
Pharma-affiliated vehicle structured without a right of first refusal; four deals this year.
- Pharma CVC
- Series B and later
- Strategic
- No ROFR
- h•••••@vantbrookepv.com Locked
- linkedin.com/in/•••••• Locked
- 05
Philippa Nkemdirim-Vasseur
Head of Venture Philanthropy · The Ashfen Foundation
Bethesda, MD
Non-dilutive awards in a single indication; new cycle opens for applications in October.
- Foundation capital
- Non-dilutive
- Indication-locked
- Cycle opening
- p•••••@ashfenfoundation.org Locked
- linkedin.com/in/•••••• Locked
- 06
Gustavo Aiyegbeni-Whitlocke
Principal · Ferrisway Instruments Fund
Boulder, CO
Underwrites tools companies on ARR and gross margin; two deals since the mandate opened.
- Tools and instrumentation
- Series A
- Revenue diligence
- New mandate
- g•••••@ferrisway.fund Locked
- linkedin.com/in/•••••• Locked
Unlock the full Biotech Investors list
The other 225 profiles are in Articuler. A free account runs 3 directory matches a day — every match returns full profiles with verified emails and LinkedIn URLs. Upgrade for unlimited matches, filtering and export.
Sign in to unlock the full listFree account · No credit card · Takes about 30 seconds
Opens Articuler search for “Investors backing biotech and life science startups”
Frequently asked questions
- What is the practical difference between a platform investor and an asset investor?
- What they think they are buying. The 84 platform-first investors are underwriting a machine that can produce many programmes and will discount any single one. The 52 asset-first investors are underwriting one molecule and want the clinical and regulatory case for it in detail. Pitching a platform story to an asset investor tends to read as an absence of conviction about the lead programme, which is fatal in that room.
- Should a first-time biotech founder approach a venture creation firm?
- Only with the trade understood. Those 27 firms build companies in-house — they will supply capital, space, a CFO and often the chair, and in exchange they hold board control from the start. For a scientific founder without company-building experience that can be the fastest path to a real programme, and for a founder who wants to run the company it is usually the wrong door.
- Is foundation money worth the effort?
- For 30 of the sources here, the capital is non-dilutive and tied to a disease area rather than a return profile, which makes it the cheapest money in the sector on paper. The cost is scope: the grant or venture-philanthropy agreement often constrains which indications the programme can pursue, and those constraints outlive the money. Read the field-of-use clause before the cheque size.
- When does pharma corporate venture make sense?
- 34 of these are pharma-affiliated. Early on, the strategic signal and the scientific diligence are genuinely valuable, and the funds usually structure to avoid a formal right of first refusal. The complication arrives later — an existing pharma investor on the cap table changes how every other potential acquirer reads the company, and that effect is hard to reverse.
- How do I know an investor is actually deploying rather than just taking meetings?
- Fund vintage and recent cheque activity, both of which sit behind the gate. A firm four years into a fund with most of the reserve allocated will meet you and cannot move; a firm that closed a vehicle in the last eighteen months is under pressure to deploy. That distinction saves more time than any thesis filter does.
- Are tools and instrumentation investors included in a biotech list?
- 47 are, because for a company selling into R&D they are the relevant capital and they are consistently mislabelled in general VC directories. They underwrite on revenue and gross margin rather than clinical probability, so the diligence resembles enterprise software far more than therapeutics, and founders who prepare a therapeutics-style deck for them lose the room.